Investopedia: Will Immunotherapy Disrupt The Oncology Market?

Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to u...

Investopedia: Pricing Still A Long-Term Risk, But Illumina Continues To Build A Sequencing Fortress

Between the disruptions created by Thermo Fisher 's (NYSE: TMO ) acquisition of Life Technologies, Roche (Nasdaq: RHHBY ) all but raisi...

Seeking Alpha: Mindray's Quarter Won't Settle Diddly

Both bulls and bears can find information in Mindray 's ( MR ) second quarter report to uphold their preexisting biases about the stoc...

Investopedia: Becton Dickinson Already Priced For Excellence

It's pretty rare to see an “Underperform” rating on a med-tech stock these days, but Becton Dickinson (NYSE: BDX ) carries more than Jo...

Investopedia: Better Margins Can't Hide Merck's Growth Challenges

In spite of pretty weak top-line results, pharma companies like Merck (NYSE: MRK ), Pfizer (NYSE: PFE ), and Bristol-Myers (NYSE: BMY ) ...

Investopedia: Pfizer Looking A Little Tired

At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE: PFE ) shares will maintain this sort ...

Investopedia: Roche Delivering Leverage, But Needs Diversification

These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq: RHHBY ), as the company continues to see double-digit growth ac...

Investopedia: Abbott Labs Making Progress On Margins, Now It Needs More Growth

Since making the split from AbbVie (Nasdaq: ABBV ), Abbott Labs (NYSE: ABT ) has had something of a mixed debut. The stock has not only l...

Seeking Alpha: Pacific Biosciences Will Go Checkers Or Wreckers

I live in NASCAR country and it's not that rare to hear the expression "going checkers or wreckers" - meaning throwing cautio...

Seeking Alpha: Celldex Turning Into A Compelling Immunotherapy Biotech

"Shoulda, coulda, woulda" will probably be my investing epitaph. While there is no shortage of investment advice telling you that...

MassDevice: The Strange Case Of The Diabetes Market

It wasn't so long ago when diabetes was one of the hot sectors of med-tech where many companies felt they had to have a presence, no m...

MassDevice: Can Johnson & Johnson Fire On All Cylinders Again?

In what has become a red-hot stock market for med-tech stocks, it's the rare quality company that hasn't taken part in the rally. ...

Investopedia: After A Good Run, Novartis Looks Fairly Valued

Like so many other pharmaceutical stocks, Novartis (NYSE: NVS ) has done pretty well for its shareholders over the past year and solidly be...

Investopedia: Roche, Reloaded

There's a saying that you'll hear used with perennially successful sports franchises – they don't rebuild, they reload. That co...

Investopedia: After A Big Rally, Pfizer Might Need Some Rest

Big Pharma has enjoyed an exceptional stretch of performance lately, reversing what had been a relatively rare period of underperformance ...

Seeking Alpha: LipoScience Gives Its Shareholders Chest Pains

There's a good reason that I always include the warning that small-cap med-techs carry above average risks, and LipoScience ( LPDX ) d...

Seeking Alpha: No News Becoming Bad News For Lexicon Pharmaceuticals

Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech re...

Seeking Alpha: Illumina Flexes Its Muscles A Bit

The strong revenue growth and lucrative margins of Illumina's ( ILMN ) core sequencing business has attracted ample competition over th...

Investopedia: Thermo Steps Up And Seals A Deal For Life Technologies

After months of speculation, Thermo Fisher (NYSE: TMO ) has brought its rumored pursuit of diversified lab equipment and supply manufacture...

Investopedia: Pharma Is Doing All The Pulling For Johnson & Johnson

While other healthcare companies including Covidien (NYSE: COV ) and Abbott (NYSE: ABT ) have seen fit to split their drug and device busi...